Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
Ainhoa Arenaza,1 Raúl Diez,2 Jordi Esteve,3 Roberta Di Nicolantonio,4 Joana Gostkorzewicz,4 Carlos Martínez,5 Diana Martínez Llinàs,6 Joaquin Martinez-Lopez,7 Pau Montesinos,8 Aída Moure-Fernández,6 Jorge Sierra,9 Joan Lluís Vinent10 1Pharmacy Department, Clínico San Carlos Hospital, Madrid, Spain;...
Saved in:
Main Authors: | Arenaza A (Author), Diez R (Author), Esteve J (Author), Di Nicolantonio R (Author), Gostkorzewicz J (Author), Martínez C (Author), Martínez Llinàs D (Author), Martinez-Lopez J (Author), Montesinos P (Author), Moure-Fernández A (Author), Sierra J (Author), Vinent JL (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
by: Pierantonio Menna, et al.
Published: (2023) -
Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
by: Amy N. Sexauer, et al.
Published: (2017) -
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019) -
Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019) -
Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor
by: Anish Paudel, et al.
Published: (2020)